Cardiovascular disease

A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV. This was the first large-scale clinical study to test a primary cardiovascular prevention strategy in this population. Advances in HIV treatment have drastically reduced […]

Sequana Medical has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its second-generation DSR product (DSR 2.0) for the treatment of congestive heart failure. Fluid accumulation in heart failure patients is caused by the retention of too much sodium. The DSR drug-based approach works in partnership with […]

A novel drug is showing promise for alleviating heart failure, a common condition associated with sleep apnoea and a reduced lifespan. The drug, known as AF-130, was tested by scientists at University of Auckland, New Zealand and the University of São Paulo, Brazil. They found it improved the heart’s ability to pump, but, equally important, […]

The primary endpoint has been achieved in a Phase II trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of atrial fibrillation (AF) to normal sinus rhythm. Acesion Pharma enrolled 63 patients with a current episode of AF in the trial and tested two intravenous doses of AP30663, 3 and 5mg/kg, compared to […]

The latest sponsored DDW Sitting Down With podcast is now available. It features Dr Michael Morton, Director and Co-founder, ApconiX, and Dr Kimberly Rockley of ApconiX, who discuss the benefits of early ion channel screening. The podcast covers the hERG ion channel and its importance in cardiac safety screening in drug discovery.  Morton and Rockley […]

The latest sponsored DDW Sitting Down With podcast features Dr Michael Morton, Director and Co-founder, ApconiX, and Dr Kimberly Rockley of ApconiX who discuss the benefits of early ion channel screening. The podcast covers the hERG ion channel and its importance in cardiac safety screening in drug discovery.  Morton and Rockley outline the options available, […]

Researchers have revealed that vaccination against Covid-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2.  The conclusions are based on analysis of the most extensive datasets in the United States by a team from the Icahn School of Medicine at Mount Sinai.  It is the […]

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin for the treatment of symptomatic chronic heart failure (HF).  The drug is approved in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).  HF […]

New trial data has shown consistent cardiovascular benefits from Novo Nordisk’s semaglutide in adults with type 2 diabetes, regardless of baseline blood sugar or kidney function. The results show that treatment with Ozempic (once-weekly semaglutide) or Rybelsus (oral semaglutide) demonstrated consistent reductions in major adverse cardiovascular events (MACE) compared with placebo. The results were presented […]

Individuals with an autoimmune disorder have a substantially higher risk of developing cardiovascular disease, a large epidemiological study has revealed.  The research – led by KU Leuven in collaboration with colleagues in the UK, including the University of Glasgow, and published in The Lancet – shows for the first time that cardiovascular risks affect autoimmune […]